Standardized Reporting for Rapid Relative Effectiveness Assessments of Pharmaceuticals

Abstract

The HTA Core Model® for Rapid REA (version 3.0) was developed to produce standardised transparent RE information of pharmaceuticals. Further piloting can provide input for possible improvements, such as further refining the assessment elements and new methodological guidance on relevant areas.

Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status

“…Transferring good quality international evidence-typically about the relative effectiveness of technologies-could be beneficial and save resources for local HTAs (Kleijnen et al, 2014). However, making decisions based on international HTA recommendations without considering limitations of transferability (especially related to treatment costs) makes more harm than good.…”

The HTA Core Model ® —10 Years of Developing an International Framework to Share Multidimensional Value Assessment

“…Further key learnings are that despite differences from and between national reports, the joint assessments included nearly all comparators, end points, trial designs, and methods of analysis that were used in national/local reports on the same technologies [18]. This means that individual organizations would be able to find the key results for their national reporting.…”

Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments

“…WP5JA1 was a 3-year collaboration between more than 30 European HTA organizations that was cofunded by the European Union and had the aim to develop methods for collaboration in the field of REA and to test these methods [8,9]. The topic of the first joint REA was "pazopanib for the treatment of advanced or metastatic renal cell carcinoma."…”